Irmarie Reyes‐Rivera

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna, Javier Sastre, Dirk Arnold et al. · The Lancet Oncology · 2012 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +10

Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy

Nicola A. Hanania, Oral Alpan, Daniel L. Hamilos et al. · Annals of Internal Medicine · 2011 · 550 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

Dirk Arnold, Thierry André, Jaafar Bennouna et al. · Journal of Clinical Oncology · 2012 · 70 citations

Medicine, Oncology, Pharmacology +10

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

Dirk Arnold, Thierry André, Jaafar Bennouna et al. · Journal of Clinical Oncology · 2012 · 39 citations

Medicine, Oncology, Pharmacology +10